In-line 3Q; MR productivity on an uptrend

Company
11 Mar 2024
5 Min read 
  • Eris Lifesciences reported in-line 3QFY24 results with core therapies outperforming the industry.
  •  The company is venturing into injectable products through the acquisition of Swiss Parenterals.
  •  Earnings estimates have been raised for FY25/FY26 due to the addition of business from Swiss Parenterals.
  •  ERIS has invested INR23b for acquisitions and is focused on improving return ratios.
  •  The upside in earnings is adequately captured in the current valuation, hence a neutral rating is reiterated.
  •  The company has a steady base business and has fueled further growth through acquisitions.
  •  ERIS has a robust pipeline and is expected to outperform the industry in the near to medium term.
  •  The company's financials and valuations show steady growth and improvement in margins.
  •  ERIS has a strong presence in the cardiac/antidiabetic segments and has invested in R&D for future growth.
  •  The company's cash flow statement shows positive cash flow from operations and investments.
  •  Overall, ERIS Lifesciences has a positive outlook and is well-positioned for future growth.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority